OHR Pharmaceutical Inc  

(Public, NASDAQ:OHRP)   Watch this stock  
Find more results for ohrp
-0.006 (-1.69%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.34 - 0.37
52 week 0.31 - 2.18
Open 0.37
Vol / Avg. 1.92M/4.06M
Mkt cap 19.18M
P/E     -
Div/yield     -
EPS -0.59
Shares 56.20M
Beta 0.48
Inst. own 13%

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.24% -83.00%
Return on average equity -82.79% -99.61%
Employees 4 -
CDP Score - -


800 3rd Ave Fl 11
NEW YORK, NY 10022-7651
United States - Map
+1-212-6828452 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin. It also owns various other compounds in earlier stages of development, including the PTP1b inhibitor Trodusquemine and related analogs.

Officers and directors

Michael A. Ferguson Chairman of the Board
Jason Scott Slakter M.D. Chief Executive Officer, Director
Age: 58
Sam Backenroth Chief Financial Officer, Vice President - Business Development
Age: 31
Avner Ingerman M.D. Chief Clinical Officer
Age: 52
June S. Almenoff M.D. Ph.D. Independent Director
Age: 60
Orin Hirschman Independent Director
Age: 47
Thomas M. Riedhammer Ph.D. Independent Director
Age: 68